Abstract: The present disclosure relates to a process for producing linear alpha olefins in high yield carried out by oligomerization of ethylene in the presence of a novel catalyst composition. The catalyst composition includes Zirconium compound, an organoaluminum compound, and at least one Lewis base selected from cyclic and acyclic ethers (i.e., di-n-butyl ether and diethyl ether). The process for oligomerization of ethylene is carried out in an inert organic solvent in the presence of said catalyst composition. The process as disclosed herein provides significantly high activity of the said catalyst composition resulting in high yield of the alpha olefins (>95 wt. %) as the product and significantly minimum polymer as by-product. The process provides higher yield of C6-C10 fraction with >60 wt. %.

Abstract: Systems and methods are presented to intelligently and seamlessly provide services to a mobile subscriber on a network based on the subscriber's usage of that or other services. A provisioning mechanism is presented that is able to correlate subscriber profiles with a plurality of Service Level Agreements (SLA) in order to intelligently determine optimal service levels. A logic unit on a network distinguishes usage patterns for a subscriber of a service, correlates the usage patterns with an SLA related to the service, and optimizes the service by modifying the SLA to reflect the usage patterns of the subscriber. Usage patterns for multiple subscribers can be correlated and stored in a segment profile. The segment profile sheds further light on what quality, level, and type of service the subscriber will find relevant. This helps maintain efficient network usage while increasing subscriber satisfaction with their level of service.

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

Abstract: The present invention discloses systems and methods for intelligently providing and charging for services on a network. A Service Controller aggregates usage history for a subscriber using a service on a network. An IICR consolidates the information into a subscriber profile and links the subscriber profile to community profiles or “segmentation” profiles. The Service Controller then seeks patterns in the subscriber profile, and adjusts the level of service for the subscriber based on said patterns. Services are dynamically provisioned and de-provisioned in real-time based on the subscriber's usage of the services, along with demographics and network conditions. Additionally, the subscriber is charged for the services based on his real-time use of the services and based on the Quality of Service (QoS) actually delivered.

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).

Abstract: Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the disclosure, without limitation, satisfy either Formula 1 or Formula 2. The present disclosure also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs and potentially comprising other active ingredients, other materials conventionally used in the formulation of pharmaceutical compositions, and mixtures thereof. The compounds and compositions of the disclosure can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.